Skip to main content
. 2020 Jun 30;11(6):492. doi: 10.1038/s41419-020-2694-7

Fig. 4. The impact of HSPG2 expression on survival in AML patients.

Fig. 4

a overall survival (OS) among whole-cohort AML. b OS among non-M3 AML. c OS among CN-AML. d leukemia-free survival (LFS) among whole-cohort AML. e LFS among non-M3 AML. f LFS among CN-AML. Non-M3 AML non M3 acute myeloid leukemia, CN-AML cytogenetically normal acute myeloid leukemia.